Syneos Health (Syneos Health) ROCE % : 2.40% (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Syneos Health ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Syneos Health's annualized ROCE % for the quarter that ended in Jun. 2023 was 2.40%.

Syneos Health ROCE % Historical Data

The historical data trend for Syneos Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health ROCE % Chart

Syneos Health Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

3.16

3.96

4.75

6.04

6.08

Syneos Health Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
ROCE %	Get a 7-Day Free Trial															7.44	8.55	4.15	-3.00	2.40

Syneos Health ROCE % Calculation

Syneos Health's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	396.962	/	( ( (8237.093 - 1654.116)	+	(8199.218 - 1724.691) )	/ 2 )
	=	396.962	/	( (6582.977	+	6474.527)	/ 2 )
	=	396.962	/	6528.752
	=	6.08 %

Syneos Health's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Mar. 2023 )		(Q: Jun. 2023 )
	=	154.152	/	( ( (8098.776 - 1687.9)	+	(8075.381 - 1627.158) )	/ 2 )
	=	154.152	/	( ( 6410.876	+	6448.223 )	/ 2 )
	=	154.152	/	6429.5495
	=	2.40 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

Syneos Health (NAS:SYNH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Syneos Health ROCE % Related Terms

Thank you for viewing the detailed overview of Syneos Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Syneos Health (Syneos Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (NAS:SYNH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1030 Sync Street, Morrisville, NC, USA, 27560-5468

Website

https://www.syneoshealth.com

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Executives

Michael J. Bonello	officer: Chief Financial Officer	4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Stanford Rudnick	officer: See remarks	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Christian Tucat	officer: Chief Business Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Michael Lee Brooks	officer: See remarks	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jonathan Olefson	officer: General Counsel & Corp Secty	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Michelle Keefe	officer: Pres., Commercial Solutions	C/O SYNEOS HEALTH,INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jason M. Meggs	officer: Chief Financial Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Donna Hildebrand Kralowetz	officer: SVP, Chief Accounting Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Matthew E. Monaghan	director	ONE INVACARE WAY, ELYRIA OH 44035
Alfonso G Zulueta	director	4925 INDIANA AVE, LISLE IL 60532
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Linda S Harty	director	MEDTRONIC PLC, 710 MEDTRONIC PARKWAY NE, LC-150, MINNEAPOLIS MN 55432
Alistair Macdonald	officer: Chief Operating Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
David S. Wilkes	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Advent International Corp/ma	10 percent owner	800 BOYLSTON STREET SUITE 3300, BOSTON MA 02199